BFAI
Jump to navigation
Jump to search
Clinical data | |
---|---|
ATC code |
|
Identifiers | |
| |
PubChem CID | |
Chemical and physical data | |
Formula | C11H11NO |
Molar mass | 173.215 g·mol−1 |
3D model (JSmol) | |
| |
|
BFAI (5,6-Benzofuranyl-2-aminoindane) is a drug that acts as a serotonin releasing agent (SSRA) and produces entactogen effects in humans, which may be useful for psychotherapeutic applications. It is closely related to MDAI but with the benzodioxole ring system replaced by benzofuran.[1]
See also
References
- ^ WO 2022/032147, Baggott M, "2-Aminoindane compounds for mental disorders or enhancement.", published 10 February 2022, assigned to Tactogen Inc.
Categories:
- Articles with short description
- Short description matches Wikidata
- Drugs not assigned an ATC code
- Chemical articles without CAS registry number
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without UNII source
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- 2-Aminoindanes
- Entactogens and empathogens
- Designer drugs
- Serotonin releasing agents
- Benzofurans
- Heterocyclic compounds with 3 rings